Bioblast Pharma

Hope should not be rare

Thomas I. H. Dubin

Thomas I. H. Dubin

Thomas I.H. Dubin

Bioblast Pharma Board of Directors Member

Thomas (Tom) Dubin joined our Board in September 2015. Mr. Dubin is an attorney and has over 20 years of senior leadership experience in the pharmaceutical and biotechnology industries. From 2001 through 2013, he was a member of the Executive Committee of Alexion Pharmaceuticals, Inc., an S&P 500 biopharmaceuticals company that discovers, develops, and commercializes lifesaving medicines for patients with ultra-rare, life-threatening disorders. As Senior Vice President and Chief Legal Officer of Alexion, Mr. Dubin led legal, government affairs, pricing and reimbursement, corporate communications, and other functions, and he held commercial responsibility for the company’s Australasia region. More recently, Mr. Dubin has advised several pharmaceutical companies on strategic matters. Prior to Alexion, he served in senior positions at ChiRex, Inc., and at Warner-Lambert Company prior to its sale to Pfizer, Inc. Mr. Dubin began his career as an attorney with Cravath, Swaine & Moore in New York City. He is a Trustee of American Jewish World Service, and a Member of Launchpad Venture Group.

Mr. Dubin received his JD from New York University School of Law, and his BA from Amherst College, cum laude.

Learn about other members of the Board of Directors of Bioblast